| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130685 | UNITED THERAP | Diketopiperazine salts for drug delivery and related methods |
Aug, 2025
(1 year, 3 months from now) | |
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US10772883 | UNITED THERAP | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US10421729 | UNITED THERAP | Microcrystalline diketopiperazine compositions and methods |
Apr, 2035
(10 years from now) | |
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Jan, 2042
(17 years from now) | |
Tyvaso Dpi is owned by United Therap.
Tyvaso Dpi contains Treprostinil.
Tyvaso Dpi has a total of 8 drug patents out of which 0 drug patents have expired.
Tyvaso Dpi was authorised for market use on 23 May, 2022.
Tyvaso Dpi is available in powder;inhalation dosage forms.
Tyvaso Dpi can be used as method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device, method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.
The generics of Tyvaso Dpi are possible to be released after 04 January, 2042.
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device; Method of treating pulmonary hypertension associated with interstitial lung dise...
Dosage: POWDER;INHALATION
TYVASO DPI family patents
